XJPX
3649
Market cap130mUSD
Oct 09, Last price
866.00JPY
1D
2.73%
1Q
-3.99%
Jan 2017
-8.65%
IPO
939.24%
Name
Findex Inc
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
FINDEX Inc., a company established in Tokyo in 1985, focuses on the creation, production, and distribution of medical technology systems across Japan. Their portfolio features Claio, a comprehensive medical imaging database management system utilized by hospitals of all sizes, and C-Note, a dedicated platform for managing patient progress notes. They also offer DocuMaker, a sophisticated document and data management solution engineered with various input tools to boost efficiency, and the GAP/GAP-screener, which is an advanced gaze analyzing perimeter. Additionally, FINDEX Inc. develops mobile applications for smartphones. Their services cater to a wide range of medical clients, including hospitals, clinics, and other healthcare institutions. The organization adopted its current name, FINDEX Inc., in November 2014, having previously operated as PSC Inc.
Key people
Teruo Aibara
President, Manager of Business Strategy Office, Representative Director · since 1994
Atsushi Fujita
Executive Officer, Director of Administration · since 2023
Hideaki Mochizuki
Executive Officer, Director of Planning and Development · since 2023
Takashi Murakami
Executive Officer · since 2023
Hiroaki Hasegawa
Director of Consulting, Director · since 2023
Keisuke Kakiuchi
Director of Hospital Solution, Director · since 2025
Koji Kondo
Director of Medical Solution, Director · since 2008
Riki Miyakawa
Manager of Security Office, Director · since 2025
Koji Yamauchi
Director · since 2016
Takahiro Yazawa
Director · since 2026
Takashi Kitada
Independent Director · since 2016
Kyoko Matsuba
Independent Director · since 2026
Akira Ono
Independent Director · since 2022
Akira Yamada
Independent Director · since 2021
Akane Yui
Independent Director · since 2026
Valuation
Title JPY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||